Ikeda 2016.

Study characteristics
Methods	Study design: Parallel‐group randomised trials Duration of trial: June 2013 to April 2014 Duration of follow‐up: 30 days Country of origin: Japan
Participants	Baseline characteristics Number randomised: 515 participants Number analysed: 511 participants Number eligible and in this review included participants: 439 Only study patients who underwent preoperative mechanical bowel preparation were included in the meta‐analysis. Intervention: MBP+oAB Number of participants [n]: 223 Age [years; mean (SD)]: 62.7 (12.6) Gender [male/female; n]: 122/101 Control: MBP Number of participants [n]: 216 Age [years, mean (SD)]: 60.1 (11.8) Gender [male/female; n]: 122/94 Inclusion criteria  Quote: ""All consecutive patients with colorectal cancer undergoing elective laparoscopic colorectal resection" Exclusion criteria Quote: ""Age less than 20 years; patients with bowel obstruction and who could not tolerate liquid intake; pregnancy; history of allergy to the drugs in the protocol; administration of antibiotics in the 2 weeks before surgery; severe dysfunction of liver, kidney, heart or lung; and synchronous resection of other major organs such as the stomach, liver or uterus" Baseline imbalances Quote: ""The patient characteristics of the two groups were well balanced at baseline"
Interventions	Comparison Intervention: MBP+oAB Control: MBP MBP Agent(s): magnesium citrate (1) and sodium picosulfate (2) Dose per administration: ‐ Time(s) of intake: at 08.00 hours (1) and at 11.00 hours (2) on the day before surgery Route: oral Concomitant medications: ‐ oAB Agent(s): metronidazole and kanamycin Dose per administration: 750 mg and 1000 mg Time(s) of intake: at 15.00 and 21.00 hours on the day before the surgery Route: oral Concomitant medications: ‐ Perioperative intravenous antibiotic prophylaxis Agent(s): cefmetazole Dose per administration: 1000 mg Time(s) of intake: Quote: ""At least 30 min before skin incision, then every 3 h during surgery until skin closure. After completion of surgery, two additional doses of intravenous prophylaxis were given within 24 h." Adherence to regimen:Quote: " "All patients except for two received the planned antimicrobial doses."
Outcomes	Outcomes sought in review and reported in trial SSI (superficional, deep and organ/space) Anastomotic leakage Incidence of postoperative ileus Length of hospital stay Outcomes sought but not reported in trial Mortality Postoperative complications (mild D/C I + II or severe D/C III+IV) Side effects of Intervention(s) Outcomes reported in trial but not used in review Intra‐abdominal abscess Urinary tract disorder Anastomotic haemorrhage Readmission within 30 days
Notes	Source of funding: ‐ Conflicts of interest: None Ethics approval: Quote:" "The study was conducted with the approval of the ethics committee of the Cancer InstituteHospital of the Japanese Foundation for Cancer Research, Tokyo, Japan" Informed consent: Written informed consent was obtained from all participants Clinical trials registration: Quote: ""This trial is registered with the UMIN Clinical Trials Registry (UMIN000019339)." Sample size calculation: Quote: ""Assuming a one‐sided α of 0⋅05, a power of 80 per cent and a 5 per cent incidence of overall SSI in both groups, 235 patients per group were needed (Dunnett–Gent test)7. Assuming an 8 per cent drop‐out rate, the planned required sample size was 253 patients."